Navigation Links
Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV

A Unique Viral Kinetics Profile

LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented additional results of a previous phase Ib, 15 day study with cyclophilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatitis C virus) co-infected patients. The data were presented at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain. Mathematical modelling of the viral decay shows that Debio 025 has a unique viral kinetics profile without signs of emerging resistance during short term treatment.

Other data from the same study showed that during treatment, Cyp-B levels decreased significantly in peripheral blood mononuclear cells (PBMCs) after treatment with Debio 025. The drop in Cyp-B levels paralleled the 3.6 log10 decrease reported earlier in this study. These human data confirm previous in vitro results that have shown that Cyp-B inhibition leads to the depletion of intracellular Cyp-B levels in the HCV replicon, as well as in other cell culture models. These are the first preliminary human data that support the hypothesis that intracellular CypB depletion is associated with significant anti-HCV activity and that CypB inhibition is a valid new target for the development of anti-HCV drugs.

"We are very excited about these results. To date, we have finalised the first two cohorts of our phase IIa study in treatment-naive mono-infected HCV patients, where we examined the effect of increasing doses of Debio 025 in combination with pegylated interferon. The Data Management Committee has analysed all safety and efficacy data and authorised the initiation of the cohort with the highest dose in the protocol," said Kamel Besseghir, CEO of Debiopharm S.A.

About Debio 025

Debio 025 is a synthetic first-in-class
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical Update Debio Cyclophilin Inhibitor for the Treatment HCV
(Date:10/3/2008)...KJAVIK, Iceland, Oct. 3 /- ...he filing of an investigational new drug,(IND) app...cule modulator,of phosphodiesterase 4 (PDE4), with...mpound is being developed as a new and potentially...ss and cognitive deficits associated,with Alzheime...
(Date:10/2/2008)...Study Will Compare the Results of Rosetta Genomics... Differentiates Squamous From non Squamous no...Methods, A Test Based on the miRview(TM) Technolog...bia University,s High Complexity Molecular Patholo..., Rosetta Genomics is Expecting to Launch miRview...
(Date:10/2/2008)...EBORG, Sweden, October 2 /- Calabar A...e study in xerostomia ("dry mouth"),patients has b...ied in 45,dry mouth patients between the ages of 2... dose for evaluation in a succeeding Phase III eff... cholinesterase inhibitor,physostigmine. It is adm...
(Date:10/2/2008)...ata Indicate Dual Modes of Action and Synergy with...ll/ -- Access Pharmaceuticals, Inc.,(OTC Bulletin ...ical,studies on Angiolix showing that by blocking ...effect as well as a direct anti-proliferative effe...human breast cancer (MX-1),Angiolix had a signifi...
Breaking Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3New Legislation Would Expedite Medicare Patient Access to Physical Therapy 16169 1New Legislation Would Expedite Medicare Patient Access to Physical Therapy 16169 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 1MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 3MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 1700 4Too Little Sleep Leads to Too Much Weight for Kids 16166 1Too Little Sleep Leads to Too Much Weight for Kids 16166 2Too Little Sleep Leads to Too Much Weight for Kids 16166 3Too Little Sleep Leads to Too Much Weight for Kids 16166 4New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 1New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 2New Medicare Equipment Bidding Program for Riverside California Area is Rife with Errors Says the American Association for Homecare 16164 3
...h Concentrations Reached in Key Lung Compartments,...RNewswire-FirstCall/ -- Arpida Ltd. today announce... AR-709. These radiolabelled,Human Microdose studi... , This groundbreaking study is the first ever usi...ntrations in lung compartments.,The results showed...
...vey Shows 89% of Patients Prefer Orapred ODT Over ...e/ -- Alliant,Pharmaceuticals announced today surv...T(TM) (Prednisolone sodium phosphate,orally disint...esults of the patient feedback survey involving mo...70) of the children,preferred Orapred ODT over liq...
Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3
(Date:10/6/2008).../ -- Ohio,s academic health care,industry contribu...an,increase of approximately $16.5 billion since 2...g one in 12 Ohioans, according to a recent study,c... Quantifying academic medicine,s economic impact ... the report underscores the significant role,Ohio,...
(Date:10/6/2008)...women suffer with symptoms of menopause as House l...an. But the effects of our current economic crisis...ngly difficult for U.S. women to cope with the cos...new cost effective drug-free guidelines to help wo..., Las Vegas, NV (PRWEB) Oc...
(Date:10/6/2008)...ire-FirstCall/ -- SAP AG (NYSE: SAP ),today annou...vice president,of the Healthcare industry business... Mr. Papandrea will help drive SAP,s industry lead...utions to healthcare,organizations around the worl...he 3rd annual Ambassadors Dinner and the U.S.-EU e...
(Date:10/5/2008)...help detect serious bacterial infections (SBIs) li...tions in young infants who come to the emergency d...e. Researchers at Children,s Hospital Boston, coll...University, show that a new diagnostic marker call... risk for SBIs while potentially reducing unnecess...
Breaking Medicine News(10 mins):Health News:Academic Medicine Means Business for Ohio: $37.2 Billion Economic Impact for the State 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 2Health News:Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines 3Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 2Health News:SAP Appoints John Papandrea to Lead Healthcare Business Unit 3Health News:New test could help catch serious infections in babies 2
...far, a pioneer in emergency medicine who also was ...ation, died Sunday evening of cancer. He was 79. D...ittsburgh, was credited with establishing the coun...nary intensive care unit. He also developed the "A...
...say stress may worsen acne! Acne is a condition of...nagers and up to 25 percent of adults. While stres...claims have been unsubstantiated until now. Twenty...d in this study.Each participant had at least one ...
...say 85 percent to 90 percent of the people living ...CFS include fatigue, muscle pain, insomnia and imp..., and there's no cure. But for the 1.3 million Ame...rome, or CFS for short, a drug commonly used in ca...
...our father when you are born may affect your risk ...increased risk of schizophrenia associated with ad...zophrenia is a serious brain disorder that distort...emotions, perceives reality and relates to others....
Other Medicine News:Health News:Father of CPR dies at 79 2
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: